NCT01937780Active, not recruiting
Anal Cancer Radiotherapy Study
Anal Cancer Radiotherapy - Prospective Study of Treatment Outcome, Patient-Reported Outcomes, Utility of Imaging and Biomarkers, and Cancer Survivorship
Source: ClinicalTrials.gov · Last updated 20 Oct 2026
Brief summary (registry, in English)
This is a prospective study of patients receiving radiotherapy or chemoradiotherapy for anal cancer. Treatment effect in terms of survival and local recurrence will be analyzed. The utility of PET-CT and MRI for radiotherapy and for prediction of treatment effect will be investigated. Molecular and genetic markers in tumor and blood will be analyzed for prognostic and predictive effects. Patient-reported outcomes, such as faecal incontinence, sexual dysfunction and quality of life will be assessed. A structured intervention program for management of late effects will be evaluated. Symptom relief of palliative radiotherapy will be investigated. The main purpose of the study is to increase the knowledge of anal cancer treatment, improve treatment results, and improve anal cancer survivor care.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 75 (estimated)
- First submitted
- 28 Aug 2013
- Start date
- 4 Oct 2013
- Primary completion date
- 30 Sept 2022
- Lead sponsor
- Oslo University Hospital
- NCT number
- NCT01937780
What you commit to
- Study type: Observational
- Planned participants: 75
- From 4 Oct 2013 to the primary completion date, 30 Sept 2022
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- \- Cognitive or physical condition resulting in inability to sign informed consent or cooperation during treatment
Who the study is looking for
- Histologically verified anal squamous cell carcinoma
- Radiotherapy or chemoradiotherapy planned
- ECOG performance status 0-2
- \>= 18 years of age
- Signed informed consent and expected cooperation of the patients for treatment and follow up
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Oslo University Hospital Coordinator of this site? Confirm its status | Oslo | Norway | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.